Epilepsia · 2026
Low-intensity focused ultrasound neuromodulation for drug-resistant epilepsy: A randomized, sham-controlled crossover trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chou Chien-Chen, Shih Yen-Cheng, Chen Yi-Hsiu, Lin Po-Tso, Lin Chun-Fu, Chu Po-Chun, Liu Hao-Li, Lee Cheng-Chia, Yu Hsiang-Yu
Аннотация
OBJECTIVE: This study was undertaken to evaluate the safety, feasibility, and efficacy of low-intensity focused ultrasound (LIFU) as a noninvasive neuromodulation technique in patients with drug-resistant epilepsy (DRE).
METHODS: In this pilot, single-blind, randomized sham-controlled crossover trial, 12 patients with DRE underwent both LIFU and sham stimulation in a randomized sequence, targeting the seizure onset zone (SOZ), each followed by a 4-week observation period. Seizure frequency was analyzed as proportional change from baseline using linear mixed-effects models. An open-label extension phase evaluated longitudinal seizure outcomes following LIFU. Safety assessments included neurological examinations, magnetic resonance imaging (MRI), and neuropsychological and quality of life (QOL) measures.
RESULTS: During the crossover phase, LIFU did not significantly reduce seizure frequency compared with sham (estimate = .49, 95% confidence interval [CI] = -.04 to 1.01, p = .068). No period or sequence effects were observed. Conversely, during the open-label extension phase, seizure frequency demonstrated a significant longitudinal reduction following LIFU (β = -14.0 percentage points per month, 95% CI = -22.2 to -5.8, p = .001). Post-LIFU MRI showed no structural lesions. No significant changes were observed in anxiety, depression, or QOL scores. There were only transient mild-to-moderate adverse events reported, without serious complications.
SIGNIFICANCE: LIFU neuromodulation targeting the SOZ is safe and well tolerated. Although the primary crossover analysis did not demonstrate a statistically significant antiseizure effect, delayed seizure reduction during the extended follow-up suggests potential sustained neuromodulatory effects. Larger parallel-group trials with longer observation periods are warranted.
METHODS: In this pilot, single-blind, randomized sham-controlled crossover trial, 12 patients with DRE underwent both LIFU and sham stimulation in a randomized sequence, targeting the seizure onset zone (SOZ), each followed by a 4-week observation period. Seizure frequency was analyzed as proportional change from baseline using linear mixed-effects models. An open-label extension phase evaluated longitudinal seizure outcomes following LIFU. Safety assessments included neurological examinations, magnetic resonance imaging (MRI), and neuropsychological and quality of life (QOL) measures.
RESULTS: During the crossover phase, LIFU did not significantly reduce seizure frequency compared with sham (estimate = .49, 95% confidence interval [CI] = -.04 to 1.01, p = .068). No period or sequence effects were observed. Conversely, during the open-label extension phase, seizure frequency demonstrated a significant longitudinal reduction following LIFU (β = -14.0 percentage points per month, 95% CI = -22.2 to -5.8, p = .001). Post-LIFU MRI showed no structural lesions. No significant changes were observed in anxiety, depression, or QOL scores. There were only transient mild-to-moderate adverse events reported, without serious complications.
SIGNIFICANCE: LIFU neuromodulation targeting the SOZ is safe and well tolerated. Although the primary crossover analysis did not demonstrate a statistically significant antiseizure effect, delayed seizure reduction during the extended follow-up suggests potential sustained neuromodulatory effects. Larger parallel-group trials with longer observation periods are warranted.